CME/CE from MPR


MPR delivers practical, up-to-date drug information to healthcare professionals. Using the expertise gained from 25 years of providing point-of-care drug tools, MPR has now created a drug review course exclusively for myCME.com. See below for a list of each quarter's courses. Click here to visit MPR's website.




Latest Courses

Clinical Review

New-Drug Review from MPR (April 2014)

1.00 Credits


MPR Drug News


FDA: More Ways to Reduce Spread of Infections From Duodenoscopes

The Food and Drug Administration (FDA) has issued a list of supplemental duodenoscope reprocessing measures to further reduce the risk of infection and increase the safety of these medical devices.

Par Approved for Generic Sodium Edecrin

Par Pharmaceuticals announced that the Food and Drug Administration (FDA) has approved Ethacrynate Sodium for Injection, the first generic version of Aton Pharma's Sodium Edecrin.

MS Drug Linked to Definite PML: New Warning Added

The Food and Drug Administration (FDA) confirmed that a case of definite progressive multifocal leukoencephalopathy (PML) and probable PML have been reported in patients taking Gilenya (fingolimod; Novartis) for multiple sclerosis.

Kynamro Demonstrates Efficacy in Heterozygous Familial Hypercholesterolemia

The Phase 3 study of Kynamro (mipomersen sodium; Isis) met its primary endpoint in patients with severe heterozygous familial hypercholesterolemia (severe HeFH).

Study: Triple Therapy No Better Than Dual for Acute MI, A-Fib

Clinicians should carefully consider the risks and benefits of triple therapy, as new research reports that in older patients with acute myocardial infarction (MI) and atrial fibrillation (AF), triple therapy did not reduce the risk of major cardiovascular events but was associated with a greater risk of bleeding.